astrazeneca glp 1 pipeline GPCR Targets and at the JP Morgan Healthcare Conference 2024 (2) GLP-1 Pipeline Update: November 2025

Stimulant-Free Energy:Experience a natural boost of energy without any stimulants

12,13 One case study looked at NAD+ 150mg sublingually daily for migraine, and though the patient reported good control of migraines with ongoing treatment, bioavailability was not assessed

Exercise tolerance may be a concern

The discovery of glucagon-like peptide 1 (GLP- 1) analogs pointed to the significant promise of gut hormones in the management of T2DM and obesity

The Case Against Injection Injection is often framed as topical but better same molecule, better delivery, systemic reach

Clinical Trial Design for Accelerated Drug Approval Despite the exciting potential for GLP-1 drugs to treat a range of conditions beyond obesity and diabetes, obtaining drug approval for new indications for use remains a daunting task due to the considerable time, effort, and resources required to conduct the necessary clinical trials